Semaglutide
Semaglutide is a modern peptide-based medicine used in the treatment of type 2 diabetes and, in higher doses, chronic weight management. By mimicking the action of a natural hormone involved in appetite and glucose regulation, semaglutide helps improve blood sugar control and supports weight reduction in many patients.
Semaglutide is developed by Novo Nordisk and is marketed under several trade names, including Ozempic, Wegovy and Rybelsus.
How semaglutide works
Semaglutide belongs to a class of medicines called GLP-1 receptor agonists. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that helps regulate blood glucose and appetite. Its main effects include:
Improving blood glucose control by stimulating insulin release when blood sugar levels are elevated
Reducing glucagon secretion, which helps prevent excessive glucose production in the liver
Slowing gastric emptying, which contributes to better post-meal glucose control
Reducing appetite and increasing satiety, which can support weight loss in many patients
Because of these mechanisms, semaglutide is widely used as part of the treatment strategy for type 2 diabetes and is also approved in some formulations for long-term weight management in people with obesity or overweight with related health conditions.
In addition to glucose control and weight reduction, clinical studies suggest that GLP-1 receptor agonists such as semaglutide may also provide cardiovascular benefits in certain high-risk patients.
Clinical trials and evidence
Semaglutide has been extensively studied in large clinical programs evaluating its safety and effectiveness in people with type 2 diabetes.
One of the most important studies, the SUSTAIN-6 trial, included more than 3,000 participants with type 2 diabetes who were at increased cardiovascular risk. The study showed that treatment with semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE) compared with placebo.
Across multiple clinical trials, semaglutide has consistently demonstrated:
significant reductions in HbA1c (a marker of long-term blood glucose control)
clinically meaningful weight loss in many patients
improved overall glycemic management when used alongside diet and lifestyle changes
These results have led to widespread adoption of semaglutide in modern diabetes care and obesity treatment guidelines.
Possible side effects of Semaglutide:
Like all medicines, semaglutide may cause side effects in some patients. Most commonly these are gastrointestinal symptoms, particularly during the first weeks of treatment as the body adjusts to the medication. Commonly reported side effects include:
nausea
diarrhea
constipation
abdominal discomfort
mild reactions at the injection site (for injectable forms)
These effects are usually temporary and tend to improve over time, especially when treatment is started with lower doses that are gradually increased.
References:
– Once‑Weekly Semaglutide in Adults with Overweight or Obesity (STEP‑1 Trial), New England Journal of Medicine, 2021, https://www.nejm.org/doi/pdf/10.1056/NEJMoa2032183
– The Discovery and Development of Liraglutide and Semaglutide, Knudsen & Lau, 2019 – Frontiers in Endocrinology, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00155/pdf